BioAscent invests in new state-of-the-art protein production facility

Left to Right: Michael Barrett OBE, Dr Stuart McElroy – Director of Biosciences, Dominika Kowalczyk – Senior Scientist.

INTEGRATED drug discovery services provider BioAscent has opened its state-of-the-art protein production facility in an event officiated by Professor Michael Barrett OBE.

The new facility marks the latest key investment the company has made, further strengthening its in-house drug discovery capabilities with the ability to deliver protein production in house, thereby implementing the most informative screening cascades for its customers.

The lab will be run by BioAscent’s highly skilled protein scientists, all of whom have significant post-doctoral and industrial experience in protein biochemistry, biophysics, and structural biology. The team will now be able to process samples under controlled conditions, with equipment dedicated to the expression and purification of proteins from various systems including bacteria, mammalian, and insect cells.

Significant investment has been made in specialist equipment including new FPLC (fast protein liquid chromatography) in a dedicated cooling cabinet and a high-pressure homogenizer, as well as shaking incubators, a sonicator, and a Category II tissue culture lab. A NanoTemper Tycho allows the team to determine protein stability and quality in a quick five-minute assay, and protein melting temperature can now be analysed with the QuantStudio 5.

Commenting, Stuart McElroy Director of Biosciences at BioAscent says, “Being able to access high quality protein is the foundation for success in many drug discovery projects. Previously, we were reliant on external sources for protein meaning we had less control over the quality and were sometimes limited by availability, as not all protein targets can be sourced on the reagent market.

“Having our own in-house facility means we can now rapidly generate multiple constructs or mutants to answer specific research questions during a project, such as identifying key binding site residues driving molecular recognition, providing structural biology, or tagging proteins differently to aid successful development of biophysical assays such as SPR.”

BioAscent welcomed Professor Michael Barrett OBE to officially open the facility on 20 February 2024. Professor Barrett is a Professor in Parasitology, Deputy Head of the School of Infection and Immunity at the University of Glasgow, and Chair of the Scottish Universities Life Sciences Alliance (SULSA).

For more information, visit

The Latest Stories

Commentary on Global IT Outage
New Research Reveals How Blind We Are to the Influence of AI
Recruitment specialist warns employers to look beyond tech skills for Gen AI talent
Business owners warned phones could be killing productivity levels